Thrombosis in children: Current perspective and distinct challenges

Thrombosis and Haemostasis

Volumn 88, Issue 6, 2002, Pages 900-911

  Richardson, Matthew W ^a,c   Allen, Geoffrey A ^a,b   Monahan, Paul E ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Baystate Med Cent   (United States)

Author keywords

Anticoagulation; Child; Hemostasis; Neonate; Thrombophilia; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 MACROGLOBULIN; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; DANAPAROID; ENOXAPARIN; FIBRINOLYTIC AGENT; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; HIRUDIN DERIVATIVE; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTAMINE; PROTHROMBIN; REVIPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; UROKINASE; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD CLOTTING; BONE DEMINERALIZATION; BONE PAIN; BRAIN HEMORRHAGE; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; COMPRESSION THERAPY; COST BENEFIT ANALYSIS; DEEP VEIN THROMBOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MONITORING; ECHOGRAPHY; FIBRINOLYTIC THERAPY; HEMOSTASIS; HUMAN; INCIDENCE; LABORATORY TEST; LONG TERM CARE; LUNG ANGIOGRAPHY; LUNG EMBOLISM; MAINTENANCE DRUG DOSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; OUTCOMES RESEARCH; PEDIATRICS; PHLEBOGRAPHY; PLASMA TRANSFUSION; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS;

EID: 0036916690     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613332     Document Type: Review

References (118)

1. Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D, Bernstein M, Brisson L, Cairney B, DeSai D, Grant R, Israels S, Jardine L, Luke B, Massicotte P, Silva M. Venous Thromboembolic Complications (VTE) in Children: First Analysis of the Canadian Registry of VTE. Blood 1994; 83: 1251-7.
2. Salzman EW, Hirsh J. The epidemiology, pathogenesis, and natural history of venous thrombosis. In: Coleman RW, Hirsch J, Marden V, Salzman E, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practices. 3rd ed. Philadelphia: JB Lippincott Co.; 1994; p. 1275-96.
3. Andrew M, Monagle P, Brooker L. Thromboembolic Complications During Infancy and Childhood. Hamilton, B.C.: Decker, Inc; 2000. p.5-45, 120-3, 168-74, 250-3.
4. Reverdiau-Moalic P, Delahousse B, Body G, Bardos P, Leroy J, Gruel Y. Evolution of blood coagulation activators and inhibitors in the healthy human fetus. Blood 1996; 88 (3): 900-6.
5. Mautone A, Giordano P, Montagna M, Quercia M, Altomare M, DeMattia D. Coagulation and fibrinolytic systems in the ill preterm newborn. Acta Paediatrica 1997; 86: 1100-4.
6. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992; 80(8): 1998-2005.
7. Andrew M. Developmental hemostasis: Relevance to hemostatic problems during childhood. Seminars in Thrombosis and Hemostasis 1995; 21 (4): 341-56.
8. Andrew M, Mitchell L, Vegh P, Ofosu F. Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb Haemost 1994; 72 (6): 836-42.
9. Schwarz H, Muntean W, Watzke H, Richter B, Grifin J. Low total protein S antigen but high protein S activity due to decreased c4b-binding protein in neonates. Blood 1988; 71: 562.
10. Nitschmann E, Monagle P, Andrew M. Morphological and biochemical features affecting the antithrombotic properties of the inferior vena cava in adult rabbits and rabbit pups. Pediatric Research 1998; 43: 1-6.
11. Trusen B, Ries M, Zenker M, Rauh M, Beinder E, Keuper H, Harms D. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (rt-PA). Seminars in Thrombosis and Hemostasis 1998; 24: 599-604.
12. Siegbahn A, Ruusuvaara L. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Thromb Haemost 1988; 60: 361-4.
13. Michelson A. Platelet function in the newborn. Seminars in Thrombosis and Hemostasis 1998; 24 (6): 507-12.
14. Israels S, Daniels M, McMillan E. Deficient collagen-induced activation in the newborn platelet. Pediatric Research 1990; 27: 337-43.
15. Van Cott EM, Grabowski EF. Vascular hemostasis in flowing blood in children. Seminars in Thrombosis and Hemostasis 1998; 24 (6): 583-90.
16. Grosshaupt B, Muntean W, Sedimayr P. Hyporeactivity of neonatal platelets is not caused by preactivation during birth. Eur J Pediatrics 1997; 56: 944-8.
17. Monagle P, Adams M, Mahoney M, Ali K, Barnard D, Bernstein M, Brisson L, David M, Desai S, Scully M-F, Halton J, Israels S, Jardine L, Leaker M, McCusker P, Silva M, Wu J, Anderson R, Andrew M, Massicotte P. Outcome of pediatric thromboembolic disease: A report from the Canadian Childhood Thrombophilia Registry. Pediatric Research 2000; 47 (6): 763-6.
18. Van Ommen C, Heijboer H, Buller H, Hirasing R, Heijmans H, Peters M. Venous thromboembolism in childhood: A prospective two-year registry in the Netherlands. J Pediatrics 2001; 139: 676-81.
19. Gurgey A, Aslan D. Outcome of noncatheter-related thrombosis in children: Influence of underlying or coexisting factors. J Pediatric Hematology Oncology 2001; 23 (3): 159-64.
20. David M, Andrew M. Venous thromboembolism complications in children: A critical review of the literature. J Pediatrics 1993; 123: 337-46.
21. Lanthier S, Carmant L, David M, Larbrisseau A, DeVeber G. Stroke in children: The coexistence of multiple risk factors predicts poor outcome. Neurology 2000; 54: 371-8.
22. Chabrier S, Husson B, Lasjaunias P, Landrieu P, Tarieu M. Stroke in childhood: Outcome and recurrence risk by mechanism in 59 patients. J Child Neurology 1999; 15: 290-4.
23. DeVeber G, Monagle P, Chan A, MacGregor D, Curtis R, Lee S, Vegh P, Adams M, Marzinotto V, Leaker M, Massicotte P, Lillicrap D, Andrew M. Prothrombotic disorders in infants and children with cerebral thromboembolism. Arch Neurology 1998; 55: 1539-43.
24. Ganeson V, McShane MA, Liesner R, Cookson J, Hann I, Kirkham FJ. Inherited prothrombotic states and ischaemic stroke in childhood. J Neurology, Neurosurgery and Psychiatry 1998; 65: 508-11.
25. Nuss R, Hays T, Manco-Johnson M. Childhood thrombosis. Pediatrics 1995; 96: 291-4.
26. Massicotte MP, Dix D, Monagle P, Adams M, Andrew M, Program CCT. Central venous catheter related thrombosis in children: Analysis of the Canadian Registry of venous thromboembolic complications. J Pediatrics 1998; 133: 770-6.
27. Schmidt B, Andrew M. Neonatal thrombosis: Report of a prospective Canadian and international registry. Pediatrics 1995; 96 (5): 939-43.
28. Lindblad B, Bergqvist D. Aggressive or conservative treatment in subclavian vein thrombosis. In: Eklof B, Gjores J, Thulesius O, Bergqvist D, eds. Controversies in the Management of Venous Disorders. London: Butterworth and Co.; 1989. p. 141-58.
29. Nowak-Gottl U, Von Kries R, Gobel U. Neonatal symptomatic thromboembolism in Germany: Two year survey. Arch Diseases in Childhood 1997; 76: F163-F7.
30. Roy M, Turner-Gomes S, Gill G, Mernagh J, Gillie P, Schmidt B. Incidence and diagnosis of neonatal thrombosis associated with umbilical venous catheters. Throm Haemost 1997; 78 (Suppl): 724.
31. Mocan H, Beattie TJ, Murphy AV. Renal venous thrombosis in infancy: Long-term follow-up. Pediatric Nephrology 1991; 5: 45-9.
32. Bokenkamp A, Von Kries R, Nowak-Gottl U, Gobel U, Hoyer PF. Neonatal renal venous thrombosis in Germany between 1992 and 1994: Epidemiology, treatment, and outcome. Eur J Pediatrics 2000; 159: 44-8.
33. Andrew M, Monagle P, De Veber G, Chan A. Thromboembolic disease and antithrombotic therapy in newborns. Hematology (American Society of Hematology Educational Program) 2001: 358-74.
34. De Veber G, Andrew M, Adams C, Bjornson B, Booth F, Buckley D, Camfield CS, David M, Hemphreys P, Langevin P, MacDonald EA, Gillet J, Group CPISS. Cerebral sinovenous thrombosis in children. N Engl J Med 2001; 345(6): 417-23.
35. Golomb M, MacGregor D, Domi T, Armstrong D, McCrindle B, Mayank S, De Veber G. Presumed pre- or perinatal arterial ischemic stroke: Risk factors and outcomes. Annals of Neurology 2001; 50 (2): 163-8.
36. Gunther G, Junker R, Strater R, Schobess R, Kurnik K, Nowak-Gottl U, Group CSS. Symptomatic ischemic stroke in full-term neonates: Role of acquired and genetic prothrombotic risk factors. Stroke 2000; 31: 2437-41.
37. De Veber GA, MacGregor D, Curtis R, Mayank S. Neurologic outcome in survivors of childhood arterial ischemic stroke and sinovenous thrombosis. J Child Neurology 2000; 15 (5): 316-24.
38. Lynch J, Hirtz D, De Veber G, Nelson K. Report of the National Institute of Neurological Disorders and Stroke workshop on perinatal and childhood stroke. Pediatrics 2002; 109 (1): 116-23.
39. Mauz-Korholz C, Junker R, Gobel U, Nowak-Gottl U. Prothrombotic risk factors in children with acute lymphoblastic leukemia treated with delayed E. coli asparaginase (COALL-92 and protocols). Thromb Haemost 2000; 83: 840-3.
40. Wermes C, Von Depka Prondzinski M, Lichtinghagen R, Barthels M, Welte K, Sykora K-W. Clinical relevance of gene risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatrics 1999; 15 ([Suppl 3]): S143-S6.
41. Knofler R, Siegert E, Lauterbach I, Taut-Sack H, Siegert G, Gehrisch S, Muller D, Rupprecht E, Kabus M. Clinical importance of prothrombotic risk factors in pediatric patients with malignancy-impact of central venous lines. Eur J Pediatrics 1999; 158 ([Suppl 3]): S147-S50.
42. Glaser DW, Medeiros D, Rollins N, Buchanon GR. Catheter-related thrombosis in children with cancer. J Pediatrics 2001; 138 (2): 255-9.
43. Freed M, Keane J, Rosenthal A. The use of heparinization to prevent arterial thrombosis after percutaneous cardiac catheterization in children. Circulation 1974; 50: 565.
44. Kocis KC, Snider AR, Vermilion RP, Beekman RH. Two-dimensional and doppler ultrasound evaluation of femoral arteries of infants after cardiac catheterization. Am J Cardiology 1995; 75: 642-5.
45. Bonduel M. Prethrombotic disorders in children with arterial stroke and sinovenous thrombosis. Archives of Neurology 1999; 56: 967-71.
46. Nowak-Gottl U, Junker R, Kreuz W, Von Eckardstein A, Kosch A, Nohe N, Schobess R, Ehrenforth S, Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001; 97 (4): 858-62.
47. Kirkham FJ, Prengler M, Hewes DKM, Ganesan V. Risk factors for arterial ischemic stroke in children. J Child Neurology 2000; 15: 299-307.
48. Askalan R, Laughlin S, Mayank S, Chan A, MacGregor D, Andrew M, Curtis R, Meaney B, De Veber G. Chickenpox and stroke in childhood: A study of frequency and causation. Stroke 2001; 32: 1257-62.
49. Sebire G, Meyer L, Chabrier S. Varicella as a risk factor for cerebral infarction in childhood: A case-control study. Annals of Neurology 1999; 45: 679-80.
50. David M, Manco-Johnson M, Andrew M. Diagnosis and treatment of venous thromboembolism in children and adolescents. On behalf of the Subcommittee on Perinatal Haemostasis of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74 (2): 791-2.
51. Male C, Chait P, Ginsberg JS, Hanna K, Andrew M, Halton J, Anderson R, McCusker P, Wu J, Abshire T, Cherrick I, Mahoney D, Mitchell L. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: Results of the PARKAA study. Thromb Haemost 2002; 87 (4): 593-8.
52. Mitchell L, Chait P, Ginsberg J, Hanna K, Andrew M. Comparison of venography with ultrasound for the detection of venous thrombosis in the upper body of children. Blood 1999; 94 (Suppl 1): 588a (abstract).
53. Nowak-Gottl U, Kosch A, Schlegel N. Thromboembolism in newborns, infants, and children. Thromb Haemost 2001; 86: 464-74.
54. Warrier I. Thrombotic disorders in infancy and childhood. Pediatric Annals 2001; 30: 558-63.
55. Gadian D, Calamante F, Kirkham F, Bynevelt M, Johnson C, Porter D, Chong W, Prengler M, Connelly A. Diffusion and perfusion magnetic resonance imaging in childhood stroke. J Child Neurology 2000; 15 (5): 279-83.
56. Ganeson V, Savvy LS, Chong WK, Kirkham FJ. Conventional cerebral angiography in children with ischemic stroke. Pediatric Neurology 1999; 20 (1): 38-42.
57. Lane D, Grant P. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95 (5): 1517-32.
58. Cushman M, Rosendaal F, Psaty B, Cook E, Valliere J, Kuller L, Tracy R. Factor V Leiden is not a risk for arterial vascular disease in the elderly: Results from the Cardiovascular Health Study. Thromb Haemost 1998; 79 (5): 912-5.
59. Bauer K. Update on thrombophilia. Hematology (American Society of Hematology Educational Program) 1999: 231-5.
60. Aschka I, Aumann V, Bergmann F, Budde U, Eberl W, Eckhof-Donovan S, Krey S, Nowak-Gottl U, Schobess R, Sutor A, Wendisch J, Schneppenheim R. Prevalence of factor V Leiden in children with thromboembolism. Eur J Pediatrics 1996; 155: 1009-14.
61. Nowak-Gottl U, Koch H, Aschka I, Kohlhase B, Vielhaber H, Kurlemann G, Oleszcuk-Raschke K, Kehl H, Jurgens H, Schneppenheim R. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. Br J Haematology 1996; 92 (4): 992-8.
62. Saxena R, Mohanty S, Jain Y. Activated protein C (APC) resistance in Indian children with thromboembolism. Br J Haematology 1999; 105: 313-20.
63. Zens W, Bodo Z, Plotho J, Streif W, Male C, Bernert G, Rauter L, Ebetsberger G, Kaltenbrunner K, Kurnik P, Lischka A, Paky F, Ploier R, Hofler G, Mannhalter C, Myntean W. Factor V Leiden and prothrombin gene G20210A variant in children with ischemic stroke. Thromb Haemost 1998; 80 (5): 763-6.
64. Mercuri E, Cowan F, Gupte G, Manning R, Iaffan M, Rutherford M, Edwards AD, Dubowitz L, Roberts I. Prothrombotic disorders and abnormal neurodevelopmental outcome in infants with neonatal cerebral infarction. Pediatrics 2001; 107: 1400-4.
65. Nowak-Gottl U, Strater R, Heinecke A, Junker R, Koch H-G, Schuierer G, Von Eckardstein A, Group CSS. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors for spontaneous ischemic stroke in childhood. Blood 1999; 94 (11): 3678-82.
66. Kenet G, Sadetzki S, Murad H, Martinowitz U, Rosenberg N, Gitel S, Rechavi G, Inbal A. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000; 31: 1283-8.
67. Manco-Johnson MJ, Nuss R. Thrombophilia in the infant and child. Advances in Pediatrics 2001; 48: 363-84.
68. Bonduel M, Hepner M, Sciuccati G, Torres AF, Pieroni G, Frontroth JP. Prothrombotic abnormalities in children with venous thromboembolism. J Pediatric Hematology/Oncology 2000; 22 (1): 66-72.
69. Hooper W, Dilley A, Ribiero M, Benson J, Austin H, Silva V, Rawlins P, Wenger N, Evatt B. A racial difference in the prevalence of the Arg506→Gln mutation. Thromb Res 1996; 81: 577-81.
70. Ridker PM, Miletich J, Hennekens C, Buring J. Ethnic distribution of factor V in 4047 men and women: Implications for venous thromboembolism screening. JAMA 1997; 277 (16): 1305-7.
71. Hessner M, Luhm R, Pearson S, Endean D, Friedman K, Montgomery R. Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multiplex allele-specific PCR. Thromb Haemost 1999; 81: 733-8.
72. Ho C, Chau W, Hsu H, Gau J, Chih C. Prevalence of factor V Leiden in the Chinese population. Zhonghua Yi Xue Za Zhi 1999; 62 (12): 875-8.
73. Ens GE. Laboratory evaluation of fibrinolysis. In: Stiene-Martin EA, Lotspeich-Steininger CA, Koepke JA, eds. Clinical Hematology: Principles, Procedures, Correlations. 2nd ed: Lippincott; 1998. p. 650-6.
74. Kristensen B, Malm J, Nilsson TK, Hultdin J, Carlberg B, Olsson T. Increased fibrinogen levels and acquired hypofibrinolysis in young adults with ischemic stroke. Stroke 1998; 29: 2261-7.
75. Crowther MA, Roberts J, Roberts R, Johnston M, Stevens P, Skingley P, Patrassi GM, Sartori MT, Hirsh J, Prandoni P, Weitz JI, Gent M, Ginsberg JS. Fibrinolytic variables in patients with recurrent venous thrombosis: A prospective cohort study. Thromb Haemost 2001: 85: 390-4.
76. Schulman S, Wiman B. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of Anticoagulation (DU-RAC) Trial Study Group. Thromb Haemost 1996; 75 (4): 607-11.
77. Eliasson M, Evrin P-E, Lundblad D, Asplund K, Ranby M. Influence of gender, age and sampling time on plasma fibrinolytic variables and fibrinogen: A population study. Fibrinolysis 1993; 7: 316-23.
78. Keidan I, Shahar E, Barzilay Z, Passwell J, Brand N. Predictors of outcome of stroke in infants and children based on clinical data and radiologic correlates. Acta Paediatrica 1995; 83 (7): 762-5.
79. Peters M. Postthrombotic Syndrome in Children. In: Perinatal/Pediatric Hemostasis Subcommittee SaSC, editor. International Society of Thrombosis and Haemostasis, 2001; Paris; France; 2001.
80. Marzinotto V, Choi M, Chan AKC, Andrew M. Post-thrombotic syndrome in children with previous deep venous thrombosis. Thromb Haemost 2001; 78 (Suppl 1): Abstract OC962.
81. Kistner RL, Eklof B, Masuda EM. Diagnosis of chronic venous disease of the lower extremities: The "CEAP" classification. Mayo Clinic Proceedings 1996; 71: 338-45.
82. Bergqvist D, Jendteg S, Johansen L, Persson U, Odegaard K. Cost of long-term complications of deep venous thrombosis of the lower extremities: An analysis of a defined patient population in Sweden. Annals of Internal Medicine 1997; 126 (6): 454-7.
83. Severin T, Sutor AH. Heparin-induced thrombocytopenia in children. Semin Thromb Hamost 2001; 27 (3): 293-9.
84. Schmugge M, Risch L, Huber A, Benn A, Fischer JE. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics 2002; 109 (1): e10.
85. Warkentin T, Levine M, Hirsh J, Horsewood P, Roberts R, Gent M, Kelton J. Heparin-induced thrombocytopenia in patients with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332 (20): 1330-5.
86. Monagle P, Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest 2001; 119 (1 Suppl): 344S-70S.
87. Punzalan R, Hillery C, Montgomery R, Scott C, Gill J. Low-molecular-weight heparin in thrombotic disease in children and adolescents. J Pediatric Hematology Oncology 2000; 22 (2): 137-42.
88. Dix D, Andrew M, Marzinotto V, Charpentier K, Bridge S, Monagle P, DeVeber G, Leaker M, Chan A, Massicotte M. The use of low molecular weight heparin in pediatric patients: A prospective cohort study. J Pediatrics 2000; 136 (4): 439-45.
89. Streif W, Andrew M, Marzinotto V, Massicotte P, Chan AKC, Julian JA, Mitchell L. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood 1999; 94 (9): 3007-14.
90. Cheung AM, Halton J, Dinyari M, Chan A, Shaughnessy S, Webber C.P.M. Bone mineral density (BMD) in a cohort of children on long term warfarin therapy (> 1 year). Thromb Haemost 2001; 78 (Suppl 1): Abstract OC1729.
91. Marzinotto V, Monagle P, Chan A, Massicotte P, Leaker M, Andrew M. Capillary whole blood monitoring of oral anticoagulants in children in outpatient clinics and the home setting. Pediatric Cardiology 2000; 21: 347-52.
92. Leaker M, Massicotte MP, Brooker LA, Andrwe M. Thrombolytic therapy in pediatric patients: A comprehensive review of the literature. Thromb Haemost 1996; 76 (2): 132-4.
93. Manco-Johnson MJ, Nuss R, Hays T, Krupski W, Drose J, Manco-Johnson ML. Combined thrombolytic and anticoagulant therapy for venous thrombosis in children. J Pediatrics 2000; 136 (4): 446-53.
94. Gupta AA, Leaker M, Andrew M, Massicotte P, Liu L, Benson LN, McCrindle BW. Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. J Pediatrics 2001; 139 (5): 682-8.
95. Hartmann HJ, Hussein A, Trowitzsch E, Becker J, Hennecke KH. Treatment of neonatal thrombus formation with recombinant tissue plasminogen activator: Six years experience and review of the literature. Arch Dis Child Fetal Neonatal Ed 2001 2001; 85 (1): F18-22.
96. Zenz W, Arlt F, Sodia S, Berghold A. Intracerebral hemorrhage during fibrinolytic therapy in children: A review of the literature of the last thirty years. Seminars in Thrombosis and Hemostasis 1997; 23 (3): 321-32.
97. Chalmers EA, Gibson BE. Thrombolytic therapy in the management of pediatric thromboembolic disease. Br J Haematology 1999; 104 (1): 14-21.
98. Wang M, Hays T, Nuss R, Gruppo R, Balasa R, Bagatell R, Grabowski E, Valentino L, Tsao-Wu G, Manco-Johnson MJ. Dose finding for tissue plasminogen activator (TPA) thrombolysis in children. Thromb Haemost 2001; Supplement 1: P824 (abstract).
99. Pegelow CH, Ledford M, Young JN, Zilleruelo G. Severe protein S deficiency in a newborn. Pediatrics 1992; 89 (4 part 1): 674-6.
100. Dreyfus M, Magny JF, Bridey F, Schwarz HP, Planche C, Dehan M, Tchernia G. Treatment of homozygous protein C deficiency and neonatal purpura with a purified protein C concentrate. N Engl J Med 1991; 325 (22): 1565-8.
101. Procare G. Comparison of thrombotic risk between 85 homozygotes and 481 heterozygotes carriers of the factor V Leiden mutation: Retrospective analysis from the Procare Study. Blood Coagul Fibrinol 2000; 11 (6): 511-8.
102. Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci PM. The risk of venous thromboembolism in family member with mutations in the genes of factor V or prothrombin or both. Br J Haematol 2000; 111: 1223-9.
103. Bucciarelli P, Rosendaal FR, Tripodi A, Mannuci PM, De Stefano V, Palareti G, Finazzi G, Baudo F, Quintavalla R, GIRTE (Italian Research Group on Inherited Thrombophilia). Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: A multicenter collaborative family study. Arteriosclerosis, Thrombosis, and Vascular Biology 1999; 19 (4): 1026-33.
104. Andrew M, Investigators P. A randomized control trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: The PROTEKT trial. Blood 2000; 96 (11): 492a (Abstract #2116).
105. Choi M, Andrew M. Post-thrombotic syndrome in children with previous deep venous thrombosis. Blood 2000; 96 (11): 654a (abstract #2815).
106. Meissner MH, Manzo RA, Bergelin RO, Markel A, Strandness Jr E. Deep venous insufficiency: The relationship between lysis and subsequent reflux. J Vascular Surgery 1993; 18 (4): 596-608.
107. Jacobs ML, Pourmoghadam KK, Geary EM, Reyes AT, Madan N, McGrath LB, Moore JW. Fontan's operation: Is aspirin enough? Is coumadin too much? Annals of Thoracic Surgery 2002; 73: 64-8.
108. Deitcher SR, Topoulos AP, Bartholomew JR, Kichuk-Chrisant MR. Lepirudin anticoagulation for heparin-induced thrombocytopenia. J Pediatr 2002; 140: 264-6.
109. Ranze O, Ranze P, Magnani HN, Greinacher A. Heparin-induced thrombocytopenia in paediatric patients - A review of the literature and a new case treated with danaparoid sodium. Eur J Pediatr 1999; 158: S130-S3.
110. Kawada T, Kitagawa H, Hoson M, Okada Y, Shiomura J. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation. Hematol Oncol Clin North Am 2002; 14 (2): 445-57.
111. Agu O, Hamilton G, Baker D. Graduated compression stockings in the prevention of venous thromboembolism. Br J Surg 1999; 86 (8): 992-1004.
112. Brandjes DPM, Buller HR, Heijboer H, Huisman MV, De Rijk M, Jagt H, Ten Cate JW. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349: 759-62.
113. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P. Development of the human coagulation system in the full-term infant. Blood 1987; 70 (1): 165-72.
114. Hathaway W, Corrigan J. Report of Scientific and Standardization Subcommittee on Neonatal Hemostasis: Normal coagulation data for fetuses and newborn infants. Thromb Haemost 1991; 65 (3): 323-5.
115. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatric Hematology Oncology 1990; 12: 95-104.
116. Nuss R, Chudgar U, Manco-Johnson M. Antiphospholipid antibodies and coagulation regulatory protein abnormalities in children with pulmonary emboli. J Pediatr Hematol Oncol 1997; 19: 202-7.
117. Manco-Johanson MJ, Grabowski EF, Hellgreen M, Kemahli AS, Massicotte MP, Muntean W, Peters M, Nowack-Gottl U. Laboratory testing for thrombophilia in pediatric patients. Thromb Haemost 2002; 88: 155-6.
118. Manco-Johnson MJ, Grabowski EF, Hellgreen M, Kemahli AS, Massicotte MP, Muntean W, Peters M, Schlegel N, Wang M, Nowack-Gottl U. Recommendations for tPA thrombolysis in children. Thromb Haemost 2002; 88: 157-8.